Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

GABA A receptor alpha-4/beta-3/delta

2

Histamine H1 receptor

315

Dopamine D2 receptor

297

DNA

278

Bacterial penicillin-binding protein

233

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1962

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Anxiety

2

Insomnia

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Kacker, I.K.|Zaheer, S.H.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

ChEMBL

2

ECHA (EC/EINECS)

2

EVMPD

2

FDA UNII

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

PSYCHOLEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

HYPNOTICS AND SEDATIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Hypnotics and sedatives in combination, excl. barbiturates

1

Other hypnotics and sedatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

METHAQUALONE HYDROCHLORIDE

RJQ4G25ZRH

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1962

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

GABA A receptor alpha-4/beta-3/delta

GABA A receptor alpha-4/beta-2/delta

GABA A receptor alpha-6/beta-1/delta

Conditions:

Methaqualone is a depressant that modulates the activity of the GABA receptors in the brain and nervous system. It promotes relaxation, sleepiness and sometimes a feeling of euphoria. It causes a drop in blood pressure and slows the pulse rate. These...

properties are the reason why it was initially thought to be a useful sedative and anxiolytic. Common side effects of Methaqualone include dizziness, nausea, vomiting, diarrhea, abdominal cramps, fatigue, itching, rashes, sweating, dry mouth, tingling sensation in arms and legs, seizures and its depressant effects include reduced heart rate and respiration. The drug became banned in many countries and was withdrawn from many markets in the early 1980s.

METHAQUALONE

7ZKH8MQW6T

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1962

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

GABA A receptor alpha-4/beta-3/delta

GABA A receptor alpha-4/beta-2/delta

GABA A receptor alpha-6/beta-1/delta

Conditions:

Methaqualone is a depressant that modulates the activity of the GABA receptors in the brain and nervous system. It promotes relaxation, sleepiness and sometimes a feeling of euphoria. It causes a drop in blood pressure and slows the pulse rate. These...

properties are the reason why it was initially thought to be a useful sedative and anxiolytic. Common side effects of Methaqualone include dizziness, nausea, vomiting, diarrhea, abdominal cramps, fatigue, itching, rashes, sweating, dry mouth, tingling sensation in arms and legs, seizures and its depressant effects include reduced heart rate and respiration. The drug became banned in many countries and was withdrawn from many markets in the early 1980s.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1